Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Gerard J Marek"'
Autor:
Jaymin Upadhyay, Scott J Baker, Prasant Chandran, Loan Miller, Younglim Lee, Gerard J Marek, Unal Sakoglu, Chih-Liang Chin, Feng Luo, Gerard B Fox, Mark Day
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e27839 (2011)
During wakefulness and in absence of performing tasks or sensory processing, the default-mode network (DMN), an intrinsic central nervous system (CNS) network, is in an active state. Non-human primate and human CNS imaging studies have identified the
Externí odkaz:
https://doaj.org/article/bd8d319d60d941108cea16c1a0f4051a
Autor:
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, Gerard J Marek
Publikováno v:
Journal of Psychopharmacology. 37:449-461
Background: Recent increases in opioid use and subsequent opioid use disorder are a major public health crisis in the United States. Aims: This phase 1 randomized, placebo-controlled study investigated the safety, tolerability, and pharmacokinetics (
Autor:
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, Gerard J Marek
Publikováno v:
Journal of Psychopharmacology. 37:144-154
Background: There is an unmet need for therapeutics with greater efficacy and tolerability for the treatment of opioid use disorder (OUD). ASP8062 is a novel compound with positive allosteric modulator activity on the γ-aminobutyric acid type B rece
Autor:
Mototsugu, Ito, Anna, Spence, Mary Beth, Blauwet, Nakyo, Heo, Ronald, Goldwater, Paul, Maruff, Gerard J, Marek
Publikováno v:
Journal of Psychopharmacology. 36:756-767
Background: ASP8062 is a novel orally active GABAB receptor positive allosteric modulator in clinical development for the treatment of alcohol use disorder (AUD) and opioid use disorder (OUD). Aims: This study assessed the potential pharmacokinetic/p
Autor:
Mototsugu Ito, Tomasz Wojtkowski, Ronald A. Smulders, Akihiro Yamada, Ronald Goldwater, Akira Koibuchi, Tolga Uz, Sitra Tauscher-Wisniewski, Gerard J. Marek
Publikováno v:
Muscle & Nerve. 65:110-120
Introduction/aims ASP0367, or bocidelpar sulfate, is an orally administered small molecule that potently and selectively modulates peroxisome proliferator-activated receptor δ (PPARδ) to address mitochondrial dysfunction occurring in diseases inclu
Autor:
Gerard J. Marek, Brian P. Ramos
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
5-Hydroxytryptamine2A (5-HT2A) receptors are enriched in layers I and Va of the rat prefrontal cortex and neocortex and their activation increases the frequency of glutamatergic excitatory post-synaptic potentials/currents (EPSP/Cs) onto layer V pyra
Externí odkaz:
https://doaj.org/article/aa7f7ecce886422f9d287e7032463cc1
Publikováno v:
Psychopharmacology
Rationale Previous research suggests that sleep polysomnography and EEG endpoints can be used to assess GABAergic activity; however, the impact of GABAB receptor positive allosteric modulators on sleep endpoints remains unclear. Objectives This phase
Autor:
Mark Walzer, Gerard J. Marek, Na Cai, Leslie M Arnold, Mary Beth Blauwet, Katherine Tracy, Paul Blahunka
Publikováno v:
Journal of Pain Research. 13:3355-3369
Purpose ASP0819 is a novel, non-opioid KCa3.1 channel opener that reverses abnormal nerve firing of primary sensory afferent nerves. Currently available treatments for fibromyalgia provide only modest relief and are accompanied by a host of adverse s
Autor:
Amit Desai, Gregory A. Light, Lev Gertsik, Tong Zhu, Paul Maruff, Tolga Uz, Lauren Benner, Ruishan Wu, Gerard J. Marek
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol 46, iss 6
ASP4345, a novel dopamine D1 receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tole
Publikováno v:
Clinical Pharmacology in Drug Development. 9:297-306
ASP8062 is an orally active γ-amino-butyric acid type B (GABAB ) receptor positive allosteric modulator currently in phase 2 development. Safety and pharmacokinetic (PK) profiles of ASP8062 were evaluated in 2 studies in healthy subjects. The first